Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Registration Number
- NCT05424627
- Lead Sponsor
- Central Hospital, Nancy, France
- Brief Summary
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement. Its pathophysiology is complex, and involves genetic, environmental and hormonal factors, leading to tolerance rupture. Among regulatory cells, Myeloid Derived Suppressor Cells (MDSCs) have been described as being increased during SLE, furthermore during flares. MDSCs are defined phenotypically as being HLA-DR-CD3-CD19-CD33+CD11b+, and either CD14+ (Monocytic MDSCs), CD15+ (Granulocytic MDSCs), or CD14-CD15- (Early-stage MDSCs). However, data regarding their immunosuppressive properties are conflicting, some studies identifying regulatory properties, while other have demonstrated a pro-inflammatory involvement through the induction of Th17 lymphocytes.
The objectives of this study is to assess the involvement of MDSC in SLE through accurate phenotypical and functional assessment, as well as characterizing their immunometabolic profile, and to identify innovative therapeutic strategies.
- Detailed Description
Systemic Lupus Erythematosus (SLE) is a chronic invalidating chronic condition, with potential articular, cutaneous, renal, and neurologic involvement. Its pathophysiology is complex, and involves genetic, environmental and hormonal factors, leading to tolerance rupture. Among regulatory cells, Myeloid Derived Suppressor Cells (MDSCs) have been described as being increased during SLE, furthermore during flares. MDSCs are defined phenotypically as being HLA-DR-CD3-CD19-CD33+CD11b+, and either CD14+ (Monocytic MDSCs), CD15+ (Granulocytic MDSCs), or CD14-CD15- (Early-stage MDSCs). However, data regarding their immunosuppressive properties are conflicting, some studies identifying regulatory properties, while other have demonstrated a pro-inflammatory involvement through the induction of Th17 lymphocytes.
To gain insight into the involvement of MDSC in SLE, both deep phenotypical characterization of MDSC and functional assessment will be performed, as well as immunometabolic characterization. This data will be correlated to the clinical presentation and activity of SLE.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 80
- Active systemic lupus erythematosus (SLEDAI > or = 1)
- Written informed consent
- Chronic or acute infection
- Other active auto-immune condition
- Active cancer
- Age below 18
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MDSC percentage among total PBMC Between 9 and 24 months if patient experience relapse during follow-up Correlation between MDSC percentage among total PBMC and Clinical activity of SLE (SLEDAI score)
- Secondary Outcome Measures
Name Time Method MDSC inflammasome activation Between 9 and 24 months if patient experience relapse during follow-up flow cytometry assessment of inflammasome activation within MDSCs
MDSC subpopulations percentage Between 9 and 24 months if patient experience relapse during follow-up flow cytometry assessment of known (Monocytic, Granulocytic, Early-stage) and unknow subpopulations of MDSC
Immunometabolic profile Between 9 and 24 months if patient experience relapse during follow-up flow cytometry assessment of metabolic profile of MDSCs
Serum cytokine levels Between 9 and 24 months if patient experience relapse during follow-up pro and anti-inflammatory cytokine levels in serum
Trial Locations
- Locations (1)
Thomas Moulinet
🇫🇷Vandoeuvre les nancy, Lorraine, France